Ventfort
Vascular peptide bioregulator
Ventfort (Vascular peptide bioregulator) is a longevity & bioregulators research compound. Vascular bioregulator — proposed to support blood-vessel wall cell function and integrity.
Ventfort quick facts
| Reported research dose (Injectable) | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~15-30 min |
| Forms | Injectable, Oral |
| Evidence level | Russian studies; limited |
| Other forms available | Oral — dosed differently |
Vascular cytogen — courses, often stacked in longevity protocols. Aimed at vessel wall rather than heart muscle, which is why it gets stacked with the cardiac peptides rather than swapped for them. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, hs-CRP, ApoB and blood pressure are the cheap readouts. Run it as an experiment you measure, not a protocol you trust.
How Ventfort works
Vascular bioregulator — proposed to support blood-vessel wall cell function and integrity.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Ventfort
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Ventfort
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Sold for vascular support, often paired with the cardiac bioregulators. Same position as the rest of the extract arm — long Russian availability, no independent evaluation.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- A vessel-derived peptide complex proposed to support endothelial and smooth muscle cell function. Endothelial dysfunction is one of the best-validated mechanisms in vascular ageing, so the target is genuinely central even where the agent is not established.
- Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Ventfort actually does
Ventfort is a peptide complex extracted from calf vessel wall, and the interesting thing about it is the source material rather than the chemistry. Like Chelohart it is a cytomax — a size-fractionated tissue extract — as distinct from the cytogen, the defined short peptide synthesized after one is identified inside such an extract Khavinson 2001. The cytogen sold for the same claim is Vesugen, Lys-Glu-Asp. Note that even that sequence is a vendor mapping rather than a sentence in a paper: Lys-Glu-Asp is peer-reviewed as a peptide, but no publication states that Vesugen is it. Ventfort has no sequence at all to argue about.
‘Blood vessel’ is not an organ, and that is not pedantry — it decides what is in the jar. Every other preparation in this family names something a knife can lift out as a unit: cortex, pineal, thymus, prostate, liver, cartilage, heart. Vasculature is distributed through all of them. An extract made in quantity from vessel wall is necessarily made from the large-caliber vessels — aorta and great vessels — because those are the only ones that can be stripped in bulk from a carcass.
Then do the arithmetic on what that wall is made of. The cell this product is sold for is the endothelium, and the endothelium is a single squamous layer on the order of 0.2 to 1 micrometer thick. A bovine aortic wall is on the order of 1 to 2 millimetres — 1,000 to 2,000 micrometers — and almost all of that is medial smooth muscle with elastic lamellae, wrapped in an adventitia of collagen and fibroblasts. So the endothelium contributes well under 1 part in 1,000 of the wall by thickness. This is ordinary histology and arithmetic rather than a measurement of any particular lot, and no vendor publishes a lot analysis that would refine it — but the conclusion is hard to escape: a preparation sold for endothelial function is made overwhelmingly from cells that are not endothelium.
Meanwhile the target it is aimed at is one of the best-specified in vascular medicine, which makes the silence conspicuous. Endothelial dysfunction has named parts: endothelial nitric oxide synthase, its cofactor tetrahydrobiopterin, the endogenous competitive inhibitor asymmetric dimethylarginine, and nitric oxide bioavailability read out as flow-mediated dilation. Not one of those appears anywhere in the literature on this product, because there is no literature on this product. The family-level mechanism — ultrashort peptides engaging DNA and chromatin, worked out as a structural motif search Kolchina 2019 and reviewed as gene regulation Khavinson 2021 — is an argument about defined molecules and cannot be run on a mixture.
Cell, rodent, human — and where it stops
This section normally walks cell to rodent to human. Here it has to start with a number that is zero. Searched by name against NCBI PubTator3 on 4 September 2026, ‘Ventfort’ returns 0 indexed records. So does ‘Ventfort peptide vessel’. Not a thin abstract, not a Russian-language paper with no translation — nothing at all. Everything below is therefore about neighboring products, and is labeled as such.
The absence is sharper than it looks, because the group ran the obvious experiment and left this tissue out. The 2015 comparison put 7 calf-tissue extracts through matched organotypic cultures at 0.01 to 100 ng/mL: Cortexin from brain cortex, Epinorm from pineal, Ventvil from liver, Prostatilen from prostate, Thymalin from thymus, Chelohart from heart, Chondrolux from cartilage Ryzhak 2015. There is no vessel extract in that list. The one preparation sold for the tissue that touches every organ is the one missing from the survey of organ extracts.
And there is a naming trap in the same sentence. The closest string to ‘Ventfort’ in that paper is ‘Ventvil’, and Ventvil is from liver. A buyer who goes looking for evidence and lands on the one indexed paper containing a Vent- preparation will be reading about hepatocytes. Nothing published connects the 2 names, and this page is not asserting that they are related; it is pointing out that the only near-match in the literature is a different organ.
What the neighbors actually show. The nearest thing to endothelial data in this whole family is a 2022 cell study in which 5 named preparations were applied to THP-1 human monocytes differentiated into macrophages Avolio 2022. All 5 suppressed TNF and interleukin-6 released after bacterial lipopolysaccharide, and peptide-treated monocytes adhered less to activated endothelial cells. Read the design carefully: the endothelium there is the surface being adhered to, not the cell being treated, and the originating institute is on the author list, so it is collaboration rather than independent replication. Ventfort is not one of the 5. The defined vascular peptide Lys-Glu-Asp does appear in the gene-expression review with a reported action on the cell-cycle inhibitors p16 and p21 Khavinson 2021 — a different molecule, sold as a different product.
The obstacles. (1) Composition, and here it is worse than the usual identity problem: because endothelium is a negligible mass fraction of the source, the extract's contents are dominated by smooth muscle and adventitial connective tissue, so ‘from vessels’ describes the anatomy of the raw material rather than the biology of the target. (2) Nothing has been given to a living animal under this name, so there is no route, no dose and no duration to report at the rodent step. (3) No human data of any kind. The independent systematic review of the family pooled 24 randomized trials over 2,245 participants with cognitive endpoints and certainty rated low to very low Alsulaimani 2021; there is no vascular arm in it, and cardiovascular medicine is precisely the field where randomized mortality evidence already exists for other things.
Ventfort pharmacokinetics — how much of it actually gets in
This compound has the one genuinely favorable pharmacokinetic argument in the entire catalog, and nobody makes it. Every other member of this family has to survive plasma and then cross an endothelium to reach cortex, pineal, prostate or myocardium — and there are 0 biodistribution studies in the family to show that any of them does. A vascular product does not have that problem. Its claimed target is the luminal endothelial surface, which is the first thing an injected molecule touches and the last thing it has to cross. On delivery alone, this is the most defensible organ claim in the series.
The counterweight is exact, and it is the same surface. The vascular endothelium is one of the most peptidase-dense surfaces in the body. Aminopeptidase N is an endothelial ectoenzyme. So is angiotensin-converting enzyme, whose own physiological substrates are the 9-residue bradykinin and the 10-residue angiotensin I — that is to say, ACE exists to chew molecules in exactly this size class, at exactly this location. The destination and the shredder are the same square micrometer of membrane. Nothing in the preparation is capped, amidated, cyclized or built with a D-amino acid to slow any of that.
The oral form, and the number the card gets wrong. Swallowed, the material meets gastric acid at roughly pH 1.5–3.5, then pancreatic proteases, then brush-border peptidases, and the only named carrier across the enterocyte handles di- and tripeptides Khavinson 2022. A size-fractionated extract is mostly longer than that by construction. The Vault lists a half-life of about 15 to 30 minutes; a mixture does not have a half-life, it has a distribution of them, and no measurement of that distribution exists for this preparation in any species. The catalog quotes one dose band, 2–5 mg per course, for both the capsule and the syringe, which cannot be right for both.
What would have to be true, and how you would know it was not
Four predictions. The last one is the one that will disappoint somebody, and it is the most important.
1. ADMA should not fall. Asymmetric dimethylarginine is the endogenous competitive inhibitor of nitric oxide synthase and the closest circulating handle on endothelial function that a person can order. It is the marker this product's own sales claim implies, and there is no proposed mechanism by which an undefined tissue extract changes the enzymes that make or clear it. Draw it before and 6 months after — the interval this site already uses for it. A fall would be the first quantitative evidence the compound does anything.
2. Lp-PLA2 should not move either. hs-CRP tells you there is inflammation somewhere; Lp-PLA2 tells you it is happening in an artery wall, which is the specificity this page needs and general inflammatory markers do not have. Retest at 6 to 12 months.
3. Flow-mediated dilation is the readout the claim deserves, and it has never been collected. Brachial artery ultrasound, 5 minutes of cuff occlusion, percentage dilation on release: a 90-minute measurement, standardized for 30 years, done in vascular labs everywhere. No member of this peptide family has a published flow-mediated dilation result — not the extracts, not the synthetics. The prediction is a null, and the value of running it is that a null here would be the first real negative datum in the category.
4. Pulse wave velocity will not move on a 10–20 day course, and hoping otherwise misreads the biology. Arterial stiffness is a structural property of elastin and collagen and their crosslinks, not a signaling state. Classic aspartic-acid racemization estimates put the half-life of human arterial elastin near 70 years — it is laid down in youth and largely not replaced. Nothing administered for 20 days remodels a matrix on that timescale. If a measured pulse wave velocity does shift, look first at the blood pressure and heart rate at the moment of measurement, both of which move it acutely and neither of which is the product.
What nobody has tested yet
Five experiments. The second one is the one this whole page has been pointing at.
1. Nobody has published a composition. Liquid chromatography with tandem mass spectrometry on a single lot would list what is in it, and it is the precondition for every other question on this page.
2. Nobody has asked whether there is any endothelium in it. This is the sharp version of experiment 1 and it has a yes-or-no answer. Search the same mass-spectrometry run for peptides mapping to endothelium-restricted proteins — von Willebrand factor, PECAM-1 — against markers of the compartments the arithmetic says dominate the source, smooth muscle alpha-actin and collagen I. The ratio of those signals is a direct measurement of what ‘from vessels’ actually means for this product. It has never been run for any tissue extract in this catalog, and it would work on all of them.
3. Nobody has added the missing arm to the group's own survey. The 2015 experiment ran 7 extracts on 7 matched tissues Ryzhak 2015. Adding a vessel extract on aortic ring explants is the same rats, the same technique and the same readout, and it is the only way the vascular claim enters that dataset at all.
4. Nobody has compared the extract with the defined peptide on endothelial cells. Human aortic endothelial cells, Ventfort against Lys-Glu-Asp, one plate, and 2 readouts that name a target rather than describing a mood: phosphorylation of endothelial nitric oxide synthase at serine 1177, and nitrite accumulation in the medium. Either the extract does something to the enzyme the product is sold on, or it does not.
5. Nobody has looked at platelets. There is no platelet aggregometry, no bleeding time and no coagulation panel published for this preparation or for any other in the family — which is remarkable given who buys a vessel product. A light-transmission aggregometry panel before and after a course, in 10 people, is a routine hematology-lab afternoon.
Ventfort — its own safety story, not its class's
Four things specific to a vessel-wall extract. None of them is in the class block.
1. The bleeding question is unasked, and the buyers are the people it would matter to. A product sold for vascular health is bought disproportionately by people already on aspirin, clopidogrel or a direct oral anticoagulant. There are 0 published platelet or coagulation data for it, so nobody can say whether the combination does anything. That is not a warning of harm; it is a statement that the most likely interaction in the real world has never been looked for. What to watch is specific and free: new bruising you cannot account for, nosebleeds, gums that bleed when you brush.
2. Measure the blood pressure, because a vasoactive effect would show up there first and because most people running this have not measured it recently. If the preparation did anything to vessel tone, the person most affected would be someone on an antihypertensive, and the sign would be lightheadedness on standing. A home cuff costs less than one course and answers a question the peptide cannot.
3. This product has a batch-variability mode the other extracts do not. For an organ extract, what varies between lots is roughly how much of the same tissue went in. Here, because endothelium is a negligible fraction of the wall by mass, what varies is which tissue — how much adventitial collagen and medial smooth muscle ended up in the grinder relative to intima. Two lots can differ in kind rather than in strength, and no certificate in routine use would show it.
4. The symptom this product is most likely to be used to ignore is a specific one. New leg pain on walking that stops with rest is claudication, and it is a marker of peripheral arterial disease and of elevated cardiovascular risk. It is also exactly the complaint a ‘vascular support’ capsule gets bought for. An ankle-brachial index takes 10 minutes in a clinic. There are 0 human studies of this compound, so a course spent on it is a course spent not answering that.
Sources read for this page
- Ryzhak AP, Chalisova NI, Lin'kova NS, Khalimov RI, Ryzhak GA, Zhekalov AN. [Polypeptides influence on tissue cell cultures regeneration of various age rats]. Advances in Gerontology 2015;28(1):97-103 [Russian] · PMID 26390619
- Khavinson VK. Tissue-specific effects of peptides. Bulletin of Experimental Biology and Medicine 2001;132(2):807-808 · PMID 11713572
- Khavinson VKh, Malinin VV, Chalisova NI, Grigor'ev EI. [Tissue-specific action of peptides in tissue culture of rats of various ages]. Advances in Gerontology 2002;9:95-100 [Russian] · PMID 12096446
- Avolio F, et al. (co-authors include Khavinson VKh). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences 2022;23(7):3607 · PMID 35408963
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Ventfort — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Ventfort — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Ventfort moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Ventfort in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Ventfort
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Ventfort — frequently asked questions
What is Ventfort?
Ventfort (Vascular peptide bioregulator) is a longevity & bioregulators research compound. Vascular bioregulator — proposed to support blood-vessel wall cell function and integrity.
Is the full Ventfort protocol on this page?
The reported research dose is on this page, along with how Ventfort works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Ventfort?
Ventfort has an approximate half-life of ~15-30 min, which is part of what determines how often it's dosed.
What forms does Ventfort come in?
Ventfort is available as: Injectable, Oral.
What's the evidence behind Ventfort?
Current evidence level: Russian studies; limited. Ventfort is offered for research purposes only and is not an approved medicine.
Ventfort inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Ventfort is used for
Ventfort appears under 1 goal in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Ventfort is the cardiac & vascular arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.